Who
Wendell Wierenga
Director
Company insider
Files Form 4 as: Director, Crinetics Pharmaceuticals; Director, Cytokinetics; Director, Dermata Therapeutics.
In numbers
- Trades disclosed
- 57
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $2.2M
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 17 Aug 2021
- Last trade
- 1 Sep 2026
- Last filed
- 1 Sep 2026
Companies traded
Activity over time
1 Oct 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 1 Sep 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code D | $9.9M116,146 at $85.00 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $478K9,730 at $49.13 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code D | $504K5,925 at $85.00 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $772K12,500 at $61.76 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $772K12,500 at $61.76 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $772K12,500 at $61.77 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $1.1M17,500 at $64.77 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $1.2M17,500 at $66.71 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $1.1M17,500 at $64.68 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $504K12,500 at $40.29 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $545K10,350 at $52.67 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $478K9,730 at $49.13 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $772K12,500 at $61.77 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $1.1M17,500 at $64.77 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $1.2M17,500 at $66.71 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $1.1M17,500 at $64.68 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $504K12,500 at $40.29 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $545K10,350 at $52.67 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code D | $9.9M116,146 at $85.00 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code D | $504K5,925 at $85.00 | filing |
News
Head to Head Survey: Maze Therapeutics (NASDAQ:MAZE) vs. Cytokinetics (NASDAQ:CYTK)CYTK · dailypolitical.com · 18 Oct 2026Head to Head Comparison: Cytokinetics (NASDAQ:CYTK) vs. Pluri (NASDAQ:PLUR)CYTK · themarketsdaily.com · 10 Oct 2026Cytokinetics (NASDAQ:CYTK) EVP Sells 3,500 Shares of StockCYTK · themarketsdaily.com · 6 Oct 2026
0 headlines in the last 90 days name Wendell Wierenga; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.